OBJECTIVE: To determine whether Chlamydia trachomatis urogenital infections persist or relapse after antimicrobial therapy by serial measurement of chlamydial-specific DNA using the polymerase chain reaction (PCR), cell cultures, and serological studies. DESIGN: Prospective evaluation of an inception cohort. SETTING: University student health clinic. PARTICIPANTS: Twenty women with culture-proven and PCR-proven C trachomatis urogenital infections. MEASUREMENTS: Incidence of persistent infection as determined by PCR, culture, and serial measurement of local and systemic antibody to C trachomatis for 5 months after doxycycline therapy. RESULTS: Prior to therapy, C trachomatis was isolated in cell culture from the cervix in 19 of 20 women, from the urethra in 13 women, and from the rectum in 13 women. All culture-positive specimens were also PCR-positive. Immediately after completion of antimicrobial therapy, all women had negative cell cultures for chlamydia. Ten of 20 culture-negative cervical specimens and two culture-negative urethral specimens had chlamydial DNA present immediately after treatment. In addition, three women had detectable DNA from cervical specimens 1 week after treatment. The presence of cervicitis (P = .01), high inclusion counts (P = .004), and serological evidence of recent infection (P = .0004) were each significantly associated with PCR positivity after treatment. All 384 subsequent cervical, rectal, and urethral specimens collected over 5 months were negative by both PCR and culture with the exception of one woman who was reinfected. Serum immunoglobulin M (IgM) titers, geometric mean serum immunoglobulin G (IgG) titers, and prevalence of local antibody to chlamydia progressively declined after treatment. CONCLUSIONS: Standard antimicrobial therapy is effective in the long-term microbiologic eradication of uncomplicated C trachomatis urogenital infections. The presence of chlamydial DNA after antimicrobial therapy is of short duration and reflects excretion of nonviable organisms rather than persistent infection.
OBJECTIVE: To determine whether Chlamydia trachomatis urogenital infections persist or relapse after antimicrobial therapy by serial measurement of chlamydial-specific DNA using the polymerase chain reaction (PCR), cell cultures, and serological studies. DESIGN: Prospective evaluation of an inception cohort. SETTING: University student health clinic. PARTICIPANTS: Twenty women with culture-proven and PCR-proven C trachomatis urogenital infections. MEASUREMENTS: Incidence of persistent infection as determined by PCR, culture, and serial measurement of local and systemic antibody to C trachomatis for 5 months after doxycycline therapy. RESULTS: Prior to therapy, C trachomatis was isolated in cell culture from the cervix in 19 of 20 women, from the urethra in 13 women, and from the rectum in 13 women. All culture-positive specimens were also PCR-positive. Immediately after completion of antimicrobial therapy, all women had negative cell cultures for chlamydia. Ten of 20 culture-negative cervical specimens and two culture-negative urethral specimens had chlamydial DNA present immediately after treatment. In addition, three women had detectable DNA from cervical specimens 1 week after treatment. The presence of cervicitis (P = .01), high inclusion counts (P = .004), and serological evidence of recent infection (P = .0004) were each significantly associated with PCR positivity after treatment. All 384 subsequent cervical, rectal, and urethral specimens collected over 5 months were negative by both PCR and culture with the exception of one woman who was reinfected. Serum immunoglobulin M (IgM) titers, geometric mean serum immunoglobulin G (IgG) titers, and prevalence of local antibody to chlamydia progressively declined after treatment. CONCLUSIONS: Standard antimicrobial therapy is effective in the long-term microbiologic eradication of uncomplicated C trachomatis urogenital infections. The presence of chlamydial DNA after antimicrobial therapy is of short duration and reflects excretion of nonviable organisms rather than persistent infection.
Authors: Laura H Bachmann; Robert E Johnson; Hong Cheng; Lauri Markowitz; John R Papp; Frank J Palella; Edward W Hook Journal: J Clin Microbiol Date: 2010-03-24 Impact factor: 5.948
Authors: Patricia J Kissinger; Scott White; Lisa E Manhart; Jane Schwebke; Stephanie N Taylor; Leandro Mena; Christine M Khosropour; Larissa Wilcox; Norine Schmidt; David H Martin Journal: Sex Transm Dis Date: 2016-10 Impact factor: 2.830
Authors: Christine M Khosropour; Julia C Dombrowski; Lindley A Barbee; Lisa E Manhart; Matthew R Golden Journal: Sex Transm Dis Date: 2014-02 Impact factor: 2.830
Authors: Lisa E Manhart; Catherine W Gillespie; M Sylvan Lowens; Christine M Khosropour; Danny V Colombara; Matthew R Golden; Navneet R Hakhu; Katherine K Thomas; James P Hughes; Nicole L Jensen; Patricia A Totten Journal: Clin Infect Dis Date: 2012-12-07 Impact factor: 9.079